Everolimus

Overview

Everolimus (RAD001) is a Rapamycin ( HY-10219 ) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy . Everolimus has potent immunosuppressive and anticancer activities.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Luminal Breast Cancer | Products > Disease Areas > HER-2 Positive Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Cytomegalovirus Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > FKBP

Product Information

• Catalog No.: HY-10218
• CAS No.: 159351-69-6
• Molecular Formula: C53H83NO14
• Molecular Weight: 958.22
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution
• Availability: In-stock

Source

Original product source